Mohamed Tarek Ahmed, Mohamed Sahar El-Deek
Department of Ophthalmology, Assiut University Hospitals, Assiut University, Assiut, Egypt.
Int J Ophthalmol. 2010;3(1):19-22. doi: 10.3980/j.issn.2222-3959.2010.01.05. Epub 2010 Mar 18.
To study plasma levels of vascular endothelial growth factor (VEGF), endothelin-1(ET-1) and nitric oxide (NO) in patients with proliferative diabetic retinopathy (PDR) before and after pan-retinal photocoagulation (PRP).
Forty patients (23 females and 17 males, mean age 48.5±12.2 years) with PDR without previous PRP therapy were studied. Blood samples were obtained before and 3 months after the last PRP session. Baseline (prelaser) plasma levels of VEGF, ET-1 and NO were compared with their levels in 30 healthy age- and sex- matched controls and also with plasma levels 3 months post-PRP.
Patients with PDR had significantly raised plasma VEGF (375±89ng/L), ET-1(20±5ng/L) and NO (135±53µmol/L) when compared with healthy control group (P<0.01). After PRP, there was a significant reduction in plasma VEGF (179±66ng/L), ET-1 (11±5ng/L) and NO (91±49µmol/L) levels at 3 months' follow-up but still significantly higher than healthy controls.
Patients with PDR demonstrate elevated VEGF, ET-1 and NO, which decrease after successful laser treatment.
研究增殖性糖尿病视网膜病变（PDR）患者在全视网膜光凝（PRP）治疗前后血管内皮生长因子（VEGF）、内皮素-1（ET-1）和一氧化氮（NO）的血浆水平。
对40例未经PRP治疗的PDR患者（23例女性，17例男性，平均年龄48.5±12.2岁）进行研究。在最后一次PRP治疗前及治疗后3个月采集血样。将VEGF、ET-1和NO的基线（激光治疗前）血浆水平与30例年龄和性别匹配的健康对照者的水平进行比较，并与PRP治疗后3个月的血浆水平进行比较。
与健康对照组相比，PDR患者的血浆VEGF（375±89ng/L）、ET-1（20±5ng/L）和NO（135±53µmol/L）显著升高（P<0.01）。PRP治疗后，随访3个月时血浆VEGF（179±66ng/L）、ET-1（11±5ng/L）和NO（91±49µmol/L）水平显著降低，但仍显著高于健康对照组。
PDR患者的VEGF、ET-1和NO水平升高，成功的激光治疗后这些水平降低。
